English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Components of the TGF-β superfamily have been well established in their intricate and multifaceted roles in cancer progression and survival. The TGF-βs have been targeted therapeutically in an attempt to modify complex tumour networks to favour cancer cell destruction. Goals of these therapies are often to attack the “hallmarks” of cancer: characteristics acquired by cancer cells via re-wiring or manipulating existing biological pathways to their survival advantage. Of the multitude of targeted therapies currently available, viral therapies have shown much promise in their efficacy of treatment. This review highlights current viral therapies targeting members of the TGF-β superfamily, with a focus on the strengths and limitations associated with this form of targeted cancer therapy.

Utility of adeno-associated viruses to target members of the TGF-&lt;i&gt;β&lt;/i&gt; superfamily in prostate cancer therapy

Utility of adeno-associated viruses to target members of the TGF-<i>β</i> superfamily in prostate cancer therapy